Black Diamond Therapeutics is a clinical stage oncology precision medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically proven targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company is advancing a robust pipeline with lead clinical stage program, BDTX-1535 targeting MasterKey mutations in both EGFR mutant-positive non-small cell lung cancer (NSCLC) and in gliobastoma (GBM), and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate oncogenic mutation families. Black Diamond’s pipeline of Masterkey therapies address significant unmet needs in patients with genetically defined cancers by potentially overcoming resistance, minimizing adverse events, addressing brain metastases, and driving durable responses.